trending Market Intelligence /marketintelligence/en/news-insights/trending/5TTO4qGtQcfI9Rzw-QGPow2 content esgSubNav
In This List

Apricus' erectile dysfunction drug launches in Lebanon

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Apricus' erectile dysfunction drug launches in Lebanon

Elis Pharmaceuticals Ltd. launched Apricus Biosciences Inc.'s erectile dysfunction drug in Lebanon.

The companies entered an agreement in 2011 to commercialize and market Vitaros in the Gulf States and part of the Middle East. The agreement yielded Apricus $100,000 in up-front payment and a further $100,000 after the drug was approved in Lebanon.

Apricus is eligible to receive up to a further $1.9 million in milestone-related payments for the product, which is approved in Canada and parts of Europe, Latin America and the Middle East.

Apricus will seek U.S. approval of the drug in 2017.